Hiroaki Ikeda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6229715/publications.pdf

Version: 2024-02-01

		759233	1125743	
15	5,369	12	13	
papers	citations	h-index	g-index	
15	15	15	8494	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Chemical augmentation of mitochondrial electron transport chains tunes T cell activation threshold in tumors., 2022, 10, e003958.		4
2	NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome. , 2022, 10 , e003811.		26
3	First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. Cancer Immunology, Immunotherapy, 2020, 69, 663-675.	4.2	22
4	CD4 + T cells support polyfunctionality of cytotoxic CD8 + T cells with memory potential in immunological control of tumor. Cancer Science, 2020, 111, 1958-1968.	3.9	19
5	Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. Journal of Clinical Investigation, 2019, 129, 1278-1294.	8.2	102
6	T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells. International Immunology, 2016, 28, 349-353.	4.0	45
7	Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination. Immunotherapy, 2016, 8, 527-540.	2.0	10
8	Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer. Clinical Cancer Research, 2015, 21, 2268-2277.	7.0	139
9	Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. Journal of Translational Medicine, 2013, 11, 246.	4.4	94
10	Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumorâ€specific CD8 ⁺ T cells. European Journal of Immunology, 2009, 39, 241-253.	2.9	50
11	Glucocorticoidâ€induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigenâ€specific CD8 ⁺ T cells with tumor regression. Cancer Science, 2009, 100, 1317-1325.	3.9	34
12	Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine, 2009, 27, 6854-6861.	3.8	45
13	Improved Expression and Reactivity of Transduced Tumor-Specific TCRs in Human Lymphocytes by Specific Silencing of Endogenous TCR. Cancer Research, 2009, 69, 9003-9011.	0.9	174
14	Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology, 2002, 3, 991-998.	14.5	4,290
15	Eradication of Established Tumors by CD8+ T Cell Adoptive Immunotherapy. Immunity, 2000, 13, 265-276.	14.3	315